Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Atezolizumab plus bevacizumab in non-clear cell, sarcomatoid kidney cancer

Rana McKay, MD, of the University of California San Diego, San Diego, CA, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. In the Phase II, open-label, single-arm study (NCT02724878), Dr Rana McKay and colleagues investigated the efficacy and safety of the combined use of atezolizumab and bevacizumab in non-clear cell and sarcomatoid differentiation RCC. She reports that promising anti-tumor activity was shown in the treated patients, in addition to a tolerable safety profile.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.